TICKERNERD
Menu
WGSWGSHealthcare · Diagnostics & Research

WGS Stock Forecast: GeneDx Holdings Corp. Price Predictions for 2026-2027

Last close, 4 Nov 2026
$69
+1.02% on the day

The 8 Wall Street analysts covering GeneDx Holdings Corp. hold a median 12-month price target of $93 — +33.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 48 of 100 as at 4 Nov 2026 — in the lower half.

Market cap
$2.1B
Ticker Nerd rank
48/ 100
Median analyst target
$93
Analysts covering
8
Revenue$114.4M+11.4% y/y
Operating income−$15.2M
Net income−$17.7M
Free cash flow−$39.1M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+7.2%
1M
−5.1%
YTD
−46.7%
1Y
−50.3%
From 52W high
−58.6%
From 52W low
+100.9%
$35
$168
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

WGS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores GeneDx Holdings Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 4 Nov 2026
48/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
76
Accruals
74
Revisions
72
Value
52
Volatility
43
Growth
41
Size
34
Momentum
34
Issuance
17

Quality (76): The business earns solid, repeatable profits on what it owns.

Issuance (17): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

WGS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on WGS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$50$100$150Jan 26Apr 26Jul 26Oct 26WGSHigh $103Median $93Low $83

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says8 analysts
8 Buy0 Hold0 Sell
Low $83Median $93High $103

The green dot is the last close — the median target sits +33.4% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 4 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
1 Oct 2026GuggenheimMaintainsBuy$74 → $83
4 Aug 2026BTIGReiteratesBuy—
4 Aug 2026BTIGReiteratesBuy$90
4 Aug 2026Canaccord GenuityMaintainsBuy$75 → $90
4 Aug 2026Canaccord GenuityMaintainsBuy—
29 June 2026GuggenheimMaintainsBuy$70 → $74
29 June 2026GuggenheimMaintainsBuy—
23 June 2026Piper SandlerMaintainsOverweight$50 → $63
23 June 2026Piper SandlerMaintainsOverweight—
5 May 2026BTIGMaintainsBuy—
5 May 2026Canaccord GenuityMaintainsBuy—
5 May 2026GuggenheimMaintainsBuy—
5 May 2026Wells FargoMaintainsOverweight—
20 Apr 2026Canaccord GenuityMaintainsBuy—
30 Mar 2026GuggenheimMaintainsBuy—
24 Feb 2026BTIGMaintainsBuy—
24 Feb 2026Piper SandlerMaintainsOverweight—
9 Feb 2026Wells FargoUpgradeOverweight—
22 Dec 2025Canaccord GenuityMaintainsBuy—
15 Dec 2025Wells FargoMaintainsEqual-Weight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

WGS appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

WGS vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 4 Nov 2026, GeneDx Holdings Corp. returned −50.3% against +14.8% for the S&P 500, dividends included.

WGS vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120Jan 26Apr 26Jul 26Oct 26WGSS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

WGS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
3
Analysts cutting
2
Fundamentals

GeneDx Holdings Corp. (WGS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
724.6×

Cheaper than 1% of US stocks

Price / sales
4.6×

Cheaper than 26% of US stocks

Price / book
8.5×

Cheaper than 10% of US stocks

EV / EBITDA
−61.8×

Cheaper than 95% of US stocks

Growth & margins
Revenue growth (YoY)
11.4%

Higher than 56% of US stocks

Earnings growth (YoY)
11.4%

Higher than 51% of US stocks

Gross margin
68.4%

Higher than 81% of US stocks

Operating margin
−15.2%

Higher than 23% of US stocks

Net margin
−23.4%

Higher than 15% of US stocks

Returns & dividend
Return on equity
−40.8%

Higher than 24% of US stocks

Return on assets
−7.9%

Higher than 29% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

GeneDx Holdings Corp. (WGS) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • GeneDx Holdings Corp. has a market value of $2.1B and an enterprise value of $2.1B.

  • Revenue in the twelve months to 30 June 2026: $454.4M. The latest quarter grew 11.4% year on year.

  • Net income over the same four quarters: −$106.4M, a −23.4% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$75.8M.

  • Shares outstanding: 29.8M.

  • Trailing P/E: 724.6×; forward P/E: 57.9× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • GeneDx Holdings Corp. employs 1,300 people — $350K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 4 Nov 2026

Data provided by Twelve Data

Peers

WGS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDiagnostics & Research
CompanyMarket capTKN rank
WGSGeneDx Holdings Corp.$2.1B48
NEONeoGenomics, Inc.$2.2B70
PSNLPersonalis, Inc.$1.7B47
OPKOPKO Health, Inc.$1.3B70
FRNMFreenome, Inc.$1.2B28
CSTLCastle Biosciences, Inc.$1.0B90
VCYTVeracyte, Inc.$4.2B93

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own GeneDx Holdings Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest WGS news & analysis

Did GeneDx Holdings Corp. Insiders Breach their Fiduciary Duties to Shareholders?

PRNewsWire · 27 Oct 2026negative

A PRNewsWire item asks GeneDx Holdings Corp. shareholders to contact a law firm about their rights and options regarding alleged breaches of fiduciary duties by company insiders. The firm says there is no cost or obligation to discuss the matter and describes its contingent-fee arrangement.

Why it matters — WGS watchers may note that shareholders are being solicited to discuss potential legal claims involving the company’s insiders.

GeneDx to Report Third Quarter 2026 Financial Results on Monday, November 9, 2026

Business Wire · 23 Oct 2026neutral

GeneDx announced it will release its third-quarter 2026 financial results after the market closes on Monday, November 9, 2026. Management will host a conference call at 4:30 p.m. Eastern Time that day to discuss financial and operating results.

Why it matters — WGS watchers can note the scheduled date and time for the company’s third-quarter results and management discussion.

GeneDx Expands Diagnostic Leadership with Long-Read Genome Sequencing, Advancing Rare Disease Diagnosis

Business Wire · 20 Oct 2026positive

GeneDx announced plans to add long-read whole genome sequencing (lrWGS) to its genome testing portfolio. The technology analyzes longer DNA stretches and may identify complex genetic variations, including some structural variants and repeat expansions that traditional short-read sequencing can miss.

Why it matters — The planned addition could broaden GeneDx’s tools for diagnosing rare diseases.

GeneDx Advances Clinical Adoption of Genomic Medicine with 27 Abstracts at ASHG 2026

Business Wire · 19 Oct 2026positive

GeneDx announced that 27 scientific abstracts were accepted for presentation at the American Society of Human Genetics 2026 Annual Meeting. The research highlights how exome and genome sequencing may support scientific discovery, earlier diagnosis and more precise care, including work on AI and machine learning for genomic interpretation.

Why it matters — The abstracts showcase GeneDx’s research activity and work related to the clinical adoption of genomic medicine.

GeneDx Presents New Evidence Advancing Genomic Newborn Screening at ICoNS 2026

Business Wire · 7 Oct 2026positive

GeneDx announced that it presented new evidence on genomic newborn screening at ICoNS 2026. The provided excerpt gives no further details about the evidence.

Why it matters — The presentation relates to GeneDx’s genomic newborn screening work, an area relevant to WGS watchers.

FAQ

Frequently asked questions about WGS stock

What is the WGS stock price forecast for 2026-2027?

The 8 Wall Street analysts covering GeneDx Holdings Corp. have a median 12-month price target of $93, with estimates ranging from $83 to $103. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is WGS stock a buy right now?

Of the 8 analysts covering GeneDx Holdings Corp., 8 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks GeneDx Holdings Corp. 48 out of 100 across roughly 4,600 US stocks as at 4 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank WGS?

As at 4 Nov 2026, GeneDx Holdings Corp. ranks 48 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (76 of 100).

Will WGS stock go up?

No one can know that. What the data says: the median 12-month target from 8 analysts implies +33.4% from the last close, and Ticker Nerd's factor model ranks GeneDx Holdings Corp. 48 out of 100 as at 4 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the WGS stock forecast for 2030?

No analyst covering GeneDx Holdings Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for WGS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $83 to $103 over the next 12 months.

How has WGS stock performed over the past year?

GeneDx Holdings Corp. returned -50.3% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does GeneDx Holdings Corp. do?

GeneDx Holdings Corp. Class A Common Stock is the equity security of GeneDx Holdings Corp., a genomics company focused on genetic testing and clinical diagnostics.

What is the latest news on WGS?

The most recent item we track (PRNewsWire, 27 Oct 2026): "Did GeneDx Holdings Corp. Insiders Breach their Fiduciary Duties to Shareholders?". A PRNewsWire item asks GeneDx Holdings Corp. shareholders to contact a law firm about their rights and options regarding alleged breaches of fiduciary duties by company insiders. The firm says there is no cost or obligation to discuss the matter and describes its contingent-fee arrangement.

Company

About GeneDx Holdings Corp.

GeneDx Holdings Corp. Class A Common Stock is the equity security of GeneDx Holdings Corp., a genomics company focused on genetic testing and clinical diagnostics. GeneDx provides pediatric and rare disease testing centered on whole exome and whole genome sequencing, along with data and information services that support more precise diagnosis and care decisions. The company also offers AI-enabled tools for sequencing analysis, interpretation, and clinical reporting across rare disease, hereditary risk, and cancer testing. Its services are used by clinicians, hospitals, and healthcare organizations that rely on genomic information to guide patient evaluation and treatment. GeneDx Holdings Corp. plays a specialized role in the healthcare market by combining laboratory testing, bioinformatics, and clinical expertise to deliver actionable genetic insights for complex medical cases.

CEO Ms. Katherine A. Stueland · 1,300 employees · United States · https://www.genedx.com